Everett Harris & Co. CA Acquires Shares of 80,341 Edwards Lifesciences Corporation $EW

Key Points

• Everett Harris & Co. CA acquired 80,341 Edwards Lifesciences shares during the second quarter, valued at approximately $7.3 million. Institutional investors collectively own 79.46% of the company.
• Analysts maintain a “Moderate Buy” consensus, with 17 Buy ratings and six Holds and an average price target of $100.27, above the stock’s reported $91.51 price.
• Edwards exceeded quarterly expectations, reporting $0.78 in EPS on $1.74 billion in revenue, with revenue up 13.6% year over year. Insiders sold 26,190 shares worth about $2.27 million during the latest quarter.

Everett Harris & Co. CA purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 80,341 shares of the medical research company's stock, valued at approximately $7,268,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hanson & Doremus Investment Management purchased a new position in Edwards Lifesciences during the first quarter valued at $25,000. JPL Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the 3rd quarter worth about $25,000. MV Capital Management Inc. purchased a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $26,000. RMG Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the 1st quarter worth about $26,000. Finally, Kemnay Advisory Services Inc. bought a new position in shares of Edwards Lifesciences in the 4th quarter worth about $27,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on EW shares. BTIG Research boosted their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Tuesday, June 30th. Barclays reaffirmed an "overweight" rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Robert W. Baird lifted their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a "neutral" rating in a report on Friday, April 24th. Weiss Ratings reissued a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Finally, Citigroup upped their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday, July 8th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $100.27.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the company's stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares of the company's stock, valued at $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 26,190 shares of company stock worth $2,269,697 over the last quarter. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Trading Down 1.1%

NYSE:EW opened at $91.51 on Friday. The company's 50 day moving average price is $88.73 and its 200-day moving average price is $84.37. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The stock has a market cap of $52.69 billion, a price-to-earnings ratio of 52.59, a PEG ratio of 2.32 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm's revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities research analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source